Sanofi Aktie

44,40 EUR ±0,00 EUR ±0,00 %

11.04.2025

STU

51,50 USD +1,84 USD +3,71 %

nachbörslich11.04.2025

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

KGV20,07

WKN662283

ISINUS80105N1054

SymbolSNY

Sanofi Aktien News

Sortieren:Datum Meistgelesen

08.04.25GlobeNewswirePress Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis

03.04.25GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - February 2025

03.04.25GlobeNewswirePress Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines

WerbungSanofi-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

28.03.25GlobeNewswirePress Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors

28.03.25GlobeNewswirePress Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD

26.03.25GlobeNewswirePress Release: Chlamydia vaccine candidate granted fast track designation by the US FDA

25.03.25GlobeNewswirePress Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis

24.03.25GlobeNewswirePress Release: Availability of the Q1 2025 Aide mémoire

20.03.25GlobeNewswirePress Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline

14.03.25PR NewswireSanofi adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu season

08.03.25GlobeNewswirePress Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

05.03.25GlobeNewswirePress release: Sanofi successfully prices EUR 1.5 billion of bond issue

25.02.25GlobeNewswirePress Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma

22.02.25GlobeNewswirePress Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease

19.02.25GlobeNewswirePress Release: Sanofi and CD&R sign Opella share purchase agreement

18.02.25GlobeNewswirePress Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid

13.02.25GlobeNewswirePress Release: Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

13.02.25GlobeNewswirePress Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study

07.02.25GlobeNewswirePress Release: Execution of a share buyback agreement for up to €2 billion

03.02.25GlobeNewswirePress Release: Sanofi announces buy back of shares from L’Oréal

31.01.25GlobeNewswirePress Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant

30.01.25GlobeNewswirePress Release: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025

29.01.25GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - December 2024

22.01.25GlobeNewswirePress Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma

21.01.25GlobeNewswirePress Release: Opella reaches study milestone for Cialis

15.01.25GlobeNewswireSanofi: Information concerning the total number of voting rights and shares – November 2024

13.01.25GlobeNewswirePress Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma

09.01.25GlobeNewswirePress Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma

23.12.24GlobeNewswirePress Release: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines

19.12.24GlobeNewswirePresse release: Jean-Paul Kress to join Sanofi's Board of Directors

17.12.24GlobeNewswirePress Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease

17.12.24GlobeNewswirePress Release: Availability of the Q4 2024 Aide-mémoire

13.12.24GlobeNewswirePress Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis

11.12.24GlobeNewswirePress Release: Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US

09.12.24GlobeNewswirePress Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients

07.12.24GlobeNewswirePress Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP

06.12.24GlobeNewswirePress Release: Availability of the revised financial statements for Sanofi excluding Opella

20.11.24GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - October 2024

15.11.24GlobeNewswirePress Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria

14.11.24GlobeNewswirePress Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma

Sanofi News

Sanofi News: auf dieser Seite finden Sie alle Sanofi News und Nachrichten zur Sanofi Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Sanofi News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Sanofi News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.